James Essell

2.7k total citations
63 papers, 1.4k citations indexed

About

James Essell is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, James Essell has authored 63 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 31 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in James Essell's work include CAR-T cell therapy research (19 papers), Multiple Myeloma Research and Treatments (15 papers) and Hematopoietic Stem Cell Transplantation (12 papers). James Essell is often cited by papers focused on CAR-T cell therapy research (19 papers), Multiple Myeloma Research and Treatments (15 papers) and Hematopoietic Stem Cell Transplantation (12 papers). James Essell collaborates with scholars based in United States, Australia and Italy. James Essell's co-authors include Ian W. Flinn, James Thompson, Thomas J. Martin, Vernon C. Smith, Peter M. Banks, Arthur R. Cohen, Paul J. Kurtin, Drore Eisen, E. Randolph Broun and James A. Reeves and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

James Essell

57 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Essell United States	19	673	502	461	286	273	63	1.4k
Yeung‐Chul Mun South Korea	22	634 0.9×	647 1.3×	422 0.9×	340 1.2×	455 1.7×	149	1.8k
P. W. Wijermans Netherlands	18	792 1.2×	438 0.9×	323 0.7×	304 1.1×	330 1.2×	49	1.6k
Sung Hwa Bae South Korea	19	382 0.6×	468 0.9×	274 0.6×	155 0.5×	291 1.1×	101	1.2k
Mark‐David Levin Netherlands	20	431 0.6×	655 1.3×	289 0.6×	405 1.4×	216 0.8×	109	1.6k
Joon Ho Moon South Korea	24	807 1.2×	561 1.1×	655 1.4×	282 1.0×	391 1.4×	175	1.9k
Roberto Castelli Italy	21	553 0.8×	230 0.5×	219 0.5×	670 2.3×	322 1.2×	86	1.6k
Massimo Martino Italy	23	1.1k 1.7×	750 1.5×	428 0.9×	220 0.8×	109 0.4×	152	1.8k
Sabine Pomplun United Kingdom	15	603 0.9×	203 0.4×	357 0.8×	274 1.0×	162 0.6×	31	1.3k
Sergio Storti Italy	20	740 1.1×	419 0.8×	235 0.5×	545 1.9×	469 1.7×	72	1.7k
C. Tom Kouroukis Canada	18	383 0.6×	460 0.9×	252 0.5×	346 1.2×	418 1.5×	49	1.2k

Countries citing papers authored by James Essell

Since Specialization

Citations

This map shows the geographic impact of James Essell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Essell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Essell more than expected).

Fields of papers citing papers by James Essell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Essell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Essell. The network helps show where James Essell may publish in the future.

Co-authorship network of co-authors of James Essell

This figure shows the co-authorship network connecting the top 25 collaborators of James Essell. A scholar is included among the top collaborators of James Essell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Essell. James Essell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ahmed, Sairah, John F. DiPersio, James Essell, et al.. (2025). NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. Blood Advances. 9(23). 6092–6095. 1 indexed citations

Ahmed, Sairah, John F. DiPersio, James Essell, et al.. (2025). NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 31(2). S11–S12. 1 indexed citations

Derman, Benjamin A., et al.. (2024). Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy. Blood. 144(Supplement 1). 5046–5046.

Ahmed, Sairah, John F. DiPersio, James Essell, et al.. (2024). NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 144(Supplement 1). 2068–2068.

Hu, Boyu, Loretta J. Nastoupil, Houston Holmes, et al.. (2024). A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.. Journal of Clinical Oncology. 42(16_suppl). 7025–7025. 9 indexed citations

Essell, James, et al.. (2024). Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics. Blood. 144(Supplement 1). 3756–3756.

Berdeja, Jesús G., Thomas G. Martin, Adriana Rossi, et al.. (2023). A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).. Journal of Clinical Oncology. 41(16_suppl). TPS8063–TPS8063. 10 indexed citations

Godwin, John E., César O. Freytes, Michael B. Maris, et al.. (2021). Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 27(3). S203–S204. 1 indexed citations

Davids, Matthew S., Bryone J. Kuss, Peter Hillmen, et al.. (2020). Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. 26(9). 2096–2103. 33 indexed citations

10.

Burke, John M., Andrei R. Shustov, James Essell, et al.. (2018). An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(8). e327–e331. 30 indexed citations

11.

Maziarz, Richard T., John Edwards, James Essell, et al.. (2018). Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data. Blood. 132(Supplement 1). 2167–2167. 1 indexed citations

12.

Schlam, Ilana, et al.. (2017). Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review. Blood. 130. 5508–5508. 1 indexed citations

13.

Hart, Lowell L., Joseph R. Mace, Edward Arrowsmith, et al.. (2015). Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 100(5). 670–676. 79 indexed citations

14.

Berdeja, Jesús G., Michael R. Savona, Joseph R. Mace, et al.. (2013). A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM). Blood. 122(21). 1937–1937. 8 indexed citations

15.

Horwitz, Mitchell E., Ivan Spasojević, Ashley Morris, et al.. (2007). Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation. 13(12). 1422–1426. 30 indexed citations

16.

Eisen, Drore, et al.. (2003). Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation. 31(1). 51–55. 37 indexed citations

17.

Eisen, Drore, James Essell, & E. Randolph Broun. (1997). Oral cavity complications of bone marrow transplantation. Seminars in Cutaneous Medicine and Surgery. 16(4). 265–272. 32 indexed citations

18.

Kereiakes, Dean J., James Essell, Charles W. Abbottsmith, Thomas M. Broderick, & John Paul Runyon. (1996). Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. The American Journal of Cardiology. 78(10). 1161–1163. 65 indexed citations

19.

Essell, James, et al.. (1993). Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia. 7(4). 410–415. 134 indexed citations

20.

Essell, James, et al.. (1992). Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.. PubMed. 10(4). 367–72. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact